Oral dryness in Sjögren's syndrome patients. Not just a question of water

Autoimmunity Reviews

Volumn 12, Issue 5, 2013, Pages 567-574

  Castro, I ^a   Sepulveda D ^a   Cortes J ^a   Quest, A F G ^a   Barrera, M J ^a   Bahamondes, V ^a   Aguilera, S ^b   Urzua U ^a   Alliende, C ^a   Molina, C ^c   Gonzalez S ^c,d   Hermoso, M A ^a   Leyton, C ^a   Gonzalez M J ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b Hospital Exequiel González Cortés   (Chile)

^c UNIVERSIDAD MAYOR   (Chile)

^d UNIVERSIDAD SAN SEBASTIÁN   (Chile)

Author keywords

Hyposulfated mucins; Salivary flow; Salivary glands; Sj gren's syndrome; Xerostomia

Indexed keywords

ACETYLCHOLINE; CALCIUM; GLYCOPROTEIN; MUCIN; MUSCARINIC M3 RECEPTOR;

CALCIUM TRANSPORT; CONCENTRATION (PARAMETERS); ENZYME DEGRADATION; EXOCRINE GLAND; GLYCOSYLATION; HUMAN; INNERVATION; KERATOCONJUNCTIVITIS SICCA; LACRIMATION; LUBRICATION; MOISTURE; MOUTH MUCOSA; NEUROTRANSMITTER RELEASE; PROTEIN TRANSPORT; REVIEW; SALIVA; SALIVARY GLAND; SALIVATION; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; WATER CONTENT; WATER TRANSPORT; XEROSTOMIA;

HUMANS; MUCINS; SALIVA; SALIVARY GLANDS; WATER; XEROSTOMIA;

EID: 84875279961     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.10.018     Document Type: Review

References (82)

1. Ramos-Casals M., Font J. Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 2005, 44:1354-1367.
2. Cruz-Tapias P., Rojas-Villarraga A., Maier-Moore S., Anaya J.M. HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2012, 11:281-287.
3. Moutsopoulos H.M. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994, 72:162-165.
4. Dawson L.J., Fox P.C., Smith P.M. Sjogrens syndrome-the non-apoptotic model of glandular hypofunction. Rheumatology (Oxford) 2006, 45:792-798.
5. Rostron J., Rogers S., Longman L., Kaney S., Field E.A. Health-related quality of life in patients with primary Sjogren's syndrome and xerostomia: a comparative study. Gerodontology 2002, 19:53-59.
6. Eliasson L., Birkhed D., Carlen A. Feeling of dry mouth in relation to whole and minor gland saliva secretion rate. Arch Oral Biol 2009, 54:263-267.
7. Tabak L.A., Levine M.J., Mandel I.D., Ellison S.A. Role of salivary mucins in the protection of the oral cavity. J Oral Pathol 1982, 11:1-17.
8. Tabak L.A. In defense of the oral cavity: structure, biosynthesis, and function of salivary mucins. Annu Rev Physiol 1995, 57:547-564.
9. Amerongen A.V., Bolscher J.G., Veerman E.C. Salivary mucins: protective functions in relation to their diversity. Glycobiology 1995, 5:733-740.
10. Amerongen A.V., Veerman E.C. Saliva-the defender of the oral cavity. Oral Dis 2002, 8:12-22.
11. Senapati S., Das S., Batra S.K. Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci 2010, 35:236-245.
12. Milne R.W., Dawes C. The relative contributions of different salivary glands to the blood group activity of whole saliva in humans. Vox Sang 1973, 25:298-307.
13. Chisholm D.M., Mason D.K. Labial salivary gland biopsy in Sjogren's disease. J Clin Pathol 1968, 21:656-660.
14. Guellec D., Cornec D., Jousse-Joulin S., Marhadour T., Marcorelles P., Pers J.O., et al. Diagnostic value of labial minor salivary gland biopsy for Sjogren's syndrome: a systematic review. Autoimmun Rev 2012 Aug 7, [Epub ahead of print].
15. Goicovich E., Molina C., Perez P., Aguilera S., Fernandez J., Olea N., et al. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjogren's syndrome patients: correlation with reduced structural integrity of acini and ducts. Arthritis Rheum 2003, 48:2573-2584.
16. Ewert P., Aguilera S., Alliende C., Kwon Y.J., Albornoz A., Molina C., et al. Disruption of tight junction structure in salivary glands from Sjogren's syndrome patients is linked to proinflammatory cytokine exposure. Arthritis Rheum 2010, 62:1280-1289.
17. Alliende C., Kwon Y.J., Brito M., Molina C., Aguilera S., Perez P., et al. Reduced sulfation of muc5b is linked to xerostomia in patients with Sjögren syndrome. Ann Rheum Dis 2008, 67:1480-1487.
18. Bahamondes V., Albornoz A., Aguilera S., Alliende C., Molina C., Castro I., et al. Changes in Rab3D expression and distribution in the acini of Sjogren's syndrome patients are associated with loss of cell polarity and secretory dysfunction. Arthritis Rheum 2011, 63:3126-3135.
19. Barrera M.J., Sanchez M., Aguilera S., Alliende C., Bahamondes V., Molina C., et al. Aberrant localization of fusion receptors involved in regulated exocytosis in salivary glands of Sjogren's syndrome patients is linked to ectopic mucin secretion. J Autoimmun 2012, 39:83-92.
20. Castro I., Aguilera S., Brockhausen I., Alliende C., Quest A.F., Molina C., et al. Decreased salivary sulphotransferase activity correlated with inflammation and autoimmunity parameters in Sjogren's syndrome patients. Rheumatology (Oxford) 2012, 51:482-490.
21. Fox R.I., Kang H.I., Ando D., Abrams J., Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 1994, 152:5532-5539.
22. Jimenez J.L., Punzon C., Navarro J., Munoz-Fernandez M.A., Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 2001, 299:753-759.
23. Nagaraju K., Cox A., Casciola-Rosen L., Rosen A. Novel fragments of the Sjogren's syndrome autoantigens alpha-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis Rheum 2001, 44:2376-2386.
24. Ghillani P., Andre C., Toly C., Rouquette A.M., Bengoufa D., Nicaise P., et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies:results of a multicentric study. Autoimmun Rev 2011, 10:509-513.
25. Ohlsson M., Skarstein K., Bolstad A.I., Johannessen A.C., Jonsson R. Fas-induced apoptosis is a rare event in Sjogren's syndrome. Lab Invest 2001, 81:95-105.
26. Manganelli P., Fietta P. Apoptosis and Sjogren syndrome. Semin Arthritis Rheum 2003, 33:49-65.
27. Garcia-Carrasco M., Fuentes-Alexandro S., Escarcega R.O., Salgado G., Riebeling C., Cervera R. Pathophysiology of Sjogren's syndrome. Arch Med Res 2006, 37:921-932.
28. Varin M.M., Guerrier T., Devauchelle-Pensec V., Jamin C., Youinou P., Pers J.O. In Sjogren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev 2012, 11:252-258.
29. Perez P., Anaya J.M., Aguilera S., Urzua U., Munroe D., Molina C., et al. Gene expression and chromosomal location for susceptibility to Sjogren's syndrome. J Autoimmun 2009, 33:99-108.
30. Fox R.I., Stern M. Sjogren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl 2002, 116:3-13.
31. Humphrey S.P., Williamson R.T. A review of saliva: normal composition, flow, and function. J Prosthet Dent 2001, 85:162-169.
32. Aps J.K., Martens L.C. Review: the physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005, 150:119-131.
33. Nelson W.J. Epithelial cell polarity from the outside looking in. News Physiol Sci 2003, 18:143-146.
34. Ambudkar I.S. Polarization of calcium signaling and fluid secretion in salivary gland cells. Curr Med Chem 2012, 19(34):5774-5781. (8).
35. Melvin J.E., Yule D., Shuttleworth T., Begenisich T. Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annu Rev Physiol 2005, 67:445-469.
36. Agre P., King L.S., Yasui M., Guggino W.B., Ottersen O.P., Fujiyoshi Y., et al. Aquaporin water channels-from atomic structure to clinical medicine. J Physiol 2002, 542:3-16.
37. Petersen O.H., Tepikin A.V. Polarized calcium signaling in exocrine gland cells. Annu Rev Physiol 2008, 70:273-299.
38. Ambudkar I.S. Dissection of calcium signaling events in exocrine secretion. Neurochem Res 2011, 36:1212-1221.
39. Konttinen Y.T., Hukkanen M., Kemppinen P., Segerberg M., Sorsa T., Malmstrom M., et al. Peptide-containing nerves in labial salivary glands in Sjogren's syndrome. Arthritis Rheum 1992, 35:815-820.
40. Zoukhri D., Hodges R.R., Dartt D.A. Lacrimal gland innervation is not altered with the onset and progression of disease in a murine model of Sjogren's syndrome. Clin Immunol Immunopathol 1998, 89:126-133.
41. Pedersen A.M., Dissing S., Fahrenkrug J., Hannibal J., Reibel J., Nauntofte B. Innervation pattern and Ca2+ signalling in labial salivary glands of healthy individuals and patients with primary Sjogren's syndrome (pSS). J Oral Pathol Med 2000, 29:97-109.
42. Zoukhri D., Kublin C.L. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjogren's syndrome. Invest Ophthalmol Vis Sci 2001, 42:925-932.
43. Szodoray P., Alex P., Brun J.G., Centola M., Jonsson R. Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004, 59:592-599.
44. Roescher N., Tak P.P., Illei G.G. Cytokines in Sjogren's syndrome. Oral Dis 2009, 15:519-526.
45. Hurst S., Collins S.M. Interleukin-1 beta modulation of norepinephrine release from rat myenteric nerves. Am J Physiol 1993, 264:G30-G35.
46. Hurst S.M., Collins S.M. Mechanism underlying tumor necrosis factor-alpha suppression of norepinephrine release from rat myenteric plexus. Am J Physiol 1994, 266:G1123-G1129.
47. Main C., Blennerhassett P., Collins S.M. Human recombinant interleukin 1 beta suppresses acetylcholine release from rat myenteric plexus. Gastroenterology 1993, 104:1648-1654.
48. Rada P., Mark G.P., Vitek M.P., Mangano R.M., Blume A.J., Beer B., et al. Interleukin-1 beta decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Res 1991, 550:287-290.
49. Jacobson L.O., Lee C., Clarke D., Strosberg A.M., Smith W.L. Effects of RS-59022-198 on the uptake and release of norepinephrine in isolated rat hearts. Proc West Pharmacol Soc 1992, 35:73-75.
50. Soliven B., Albert J. Tumor necrosis factor modulates the inactivation of catecholamine secretion in cultured sympathetic neurons. J Neurochem 1992, 58:1073-1078.
51. Zoukhri D., Kublin C.L. Impaired neurotransmission in lacrimal and salivary glands of a murine model of Sjogren's syndrome. Adv Exp Med Biol 2002, 506:1023-1028.
52. Dawson L.J., Christmas S.E., Smith P.M. An investigation of interactions between the immune system and stimulus-secretion coupling in mouse submandibular acinar cells. A possible mechanism to account for reduced salivary flow rates associated with the onset of Sjogren's syndrome. Rheumatology (Oxford) 2000, 39:1226-1233.
53. Dawson L.J., Caulfield V.L., Stanbury J.B., Field A.E., Christmas S.E., Smith P.M. Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 2005, 44:449-455.
54. Vivino F.B., Al-Hashimi I., Khan Z., LeVeque F.G., Salisbury P.L., Tran-Johnson T.K., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999, 159:174-181.
55. Fox R.I., Dixon R., Guarrasi V., Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996, 5(Suppl. 1):S31-S36.
56. Fox R.I., Chan E., Benton L., Fong S., Friedlaender M., Howell F.V. Treatment of primary Sjogren's syndrome with hydroxychloroquine. Am J Med 1988, 85:62-67.
57. Lakhanpal S., Duffy J., Griffing W.L., Conn D.L., Luthra H.S. Sjogren's syndrome: treatment with D-penicillamine and hydroxychloroquine. J Rheumatol 1985, 12:1028-1029.
58. Tishler M., Yaron I., Shirazi I., Yaron M. Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999, 58:253-256.
59. Kruize A.A., Hene R.J., Kallenberg C.G., van Bijsterveld O.P., van der Heide A., Kater L., et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993, 52:360-364.
60. Reina S., Orman B., Anaya J.M., Sterin-Borda L., Borda E. Cholinoreceptor autoantibodies in Sjogren syndrome. J Dent Res 2007, 86:832-836.
61. Bacman S., Sterin-Borda L., Camusso J.J., Arana R., Hubscher O., Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. Clin Exp Immunol 1996, 104:454-459.
62. Reina S., Sterin-Borda L., Passafaro D., Borda E. Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjogren's syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands. Arch Oral Biol 2011, 56:413-420.
63. Kiselyov K., Wang X., Shin D.M., Zang W., Muallem S. Calcium signaling complexes in microdomains of polarized secretory cells. Cell Calcium 2006, 40:451-459.
64. Caulfield V.L., Balmer C., Dawson L.J., Smith P.M. A role for nitric oxide-mediated glandular hypofunction in a non-apoptotic model for Sjogren's syndrome. Rheumatology (Oxford) 2009, 48:727-733.
65. Dawson L.J., Field E.A., Harmer A.R., Smith P.M. Acetylcholine-evoked calcium mobilization and ion channel activation in human labial gland acinar cells from patients with primary Sjogren's syndrome. Clin Exp Immunol 2001, 124:480-485.
66. Konttinen Y.T., Platts L.A., Tuominen S., Eklund K.K., Santavirta N., Tornwall J., et al. Role of nitric oxide in Sjogren's syndrome. Arthritis Rheum 1997, 40:875-883.
67. Cheng K.T., Alevizos I., Liu X., Swaim W.D., Yin H., Feske S., et al. STIM1 and STIM2 protein deficiency in T lymphocytes underlies development of the exocrine gland autoimmune disease, Sjogren's syndrome. Proc Natl Acad Sci U S A 2012, 109:14544-14549.
68. Ishikawa Y., Iida H., Ishida H. The muscarinic acetylcholine receptor-stimulated increase in aquaporin-5 levels in the apical plasma membrane in rat parotid acinar cells is coupled with activation of nitric oxide/cGMP signal transduction. Mol Pharmacol 2002, 61:1423-1434.
69. Beroukas D., Hiscock J., Jonsson R., Waterman S.A., Gordon T.P. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjogren's syndrome. Lancet 2001, 358:1875-1876.
70. Steinfeld S., Cogan E., King L.S., Agre P., Kiss R., Delporte C. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjogren's syndrome patients. Lab Invest 2001, 81:143-148.
71. Soyfoo M., Konno A., Bolaky N., Oak J., Fruman D., Nicaise C., et al. Link between inflammation and aquaporin-5 distribution in submandibular gland in Sjogren's syndrome?. Oral Dis 2012, 18:568-574.
72. Offner G.D., Troxler R.F. Heterogeneity of high-molecular-weight human salivary mucins. Adv Dent Res 2000, 14:69-75.
73. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004, 4:45-60.
74. Thornton D.J., Rousseau K., McGuckin M.A. Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 2008, 70:459-486.
75. Thornton D.J., Khan N., Mehrotra R., Howard M., Veerman E., Packer N.H., et al. Salivary mucin MG1 is comprised almost entirely of different glycosylated forms of the MUC5B gene product. Glycobiology 1999, 9:293-302.
76. Passafaro D., Sterin-Borda L., Reina S., Borda E. Cholinergic autoantibodies from primary Sjogren's syndrome inhibit mucin production via phospholipase C and cyclooxygenase-2 in the rat submandibular gland. Dent Res J (Isfahan) 2011, 8:138-145.
77. Almstahl A., Wikstrom M., Groenink J. Lactoferrin, amylase and mucin MUC5B and their relation to the oral microflora in hyposalivation of different origins. Oral Microbiol Immunol 2001, 16:345-352.
78. Saari H., Halinen S., Ganlov K., Sorsa T., Konttinen Y.T. Salivary mucous glycoprotein MG1 in Sjogren's syndrome. Clin Chim Acta 1997, 259:83-96.
79. Xu Y.X., Liu L., Caffaro C.E., Hirschberg C.B. Inhibition of Golgi apparatus glycosylation causes endoplasmic reticulum stress and decreased protein synthesis. J Biol Chem 2010, 285:24600-24608.
80. Lopez-Jornet P., Camacho-Alonso F. Quality of life in patients with Sjogren's syndrome and sicca complex. J Oral Rehabil 2008, 35:875-881.
81. Fox P.C. Salivary enhancement therapies. Caries Res 2004, 38:241-246.
82. Thomsson K.A., Prakobphol A., Leffler H., Reddy M.S., Levine M.J., Fisher S.J., Hansson G.C. The salivary mucin MG1 (MUC5B) carries a repertoire of unique oligosaccharides that is large and diverse. Glycobiology 2002 Jan, 12(1):1-14.